✦ LIBER ✦

Therapy for refractory acute graft versus host disease (aGVHD) with basiliximab (BaMab) - a selective interleukin-2 receptor (IL-2R) antagonist

✍ Scribed by V.A. Moreira; C.M. Bonfim; M.A. Bitencourt; D.C. Setubal; C. Lorenzato; J. Ruiz; J. Zanis-Netto; C.R. de Medeiros; R. Pasquini

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Therapy for severe refractory acute graf

✍ Funke, V A M; de Medeiros, C R; Setúbal, D C; Ruiz, J; Bitencourt, M A; Bonfim, 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 120 KB

Efficacy of the interleukin-2 receptor a

✍ Martin Schmidt-Hieber; Thomas Fietz; Wolfgang Knauf; Lutz Uharek; Werner Hopfenm 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

Encouraging Results with Inolimomab (Ant

✍ Jose Luis Piñana; David Valcárcel; Rodrigo Martino; M. Estela Moreno; Anna Sured 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 144 KB